home / stock / psttf / psttf short
Short Information | Prescient Therapeutics Ltd (OTCMKTS:PSTTF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 11,742 |
Total Actual Volume | 10,942 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 5 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 587 |
Average Short Percentage | 26.33% |
Is there a PSTTF Short Squeeze or Breakout about to happen?
See the PSTTF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
08-25-2022 | $0.145 | $0.145 | $0.145 | $0.145 | 2,000 | 2,000 | 100% |
08-02-2022 | $0.16 | $0.16 | $0.16 | $0.16 | 2,000 | 2,000 | 100% |
10-13-2020 | $0.055 | $0.055 | $0.055 | $0.055 | 3,000 | 3,800 | 126.67% |
09-12-2019 | $0.045 | $0.045 | $0.045 | $0.045 | 1,942 | 1,942 | 100% |
08-14-2019 | $0.0311 | $0.0311 | $0.0311 | $0.0311 | 2,000 | 2,000 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Prescient Therapeutics Ltd Company Name:
PSTTF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the results of its PTX-100 Phase 1b study at the 15th Annual T-Cell Lymphoma Forum (TCLF) in Californi...
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of Cell and Gene Therapy (ISCT)’s annual meeting. The team briefed an exp...
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL). The designation from the Office of Orphan Product...